Spectrum Pharma (SPPI) Misses Q4 EPS by 9c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Spectrum Pharma (SPPI) Misses Q4 EPS by 9c, Revenues Beat

Spectrum Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results and Pipeline Update

February 28, 2019 4:00 PM EST

Poziotinib enrollment completed in previously treated EGFR cohort (cohort 1) of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS® (eflapegrastim) Biologics License Application (BLA) was submitted to the FDA Q4 Revenues were $29.4 million, including $28.0 million in product sales; full year revenues were $109.3 million including $104.5 million in product sales

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and year ended December 31, 2018.

... More